Silence Therapeutics plc
SLN
Price:
$6.69
Market Cap:
$316.00M
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-assoc...[Read more]
Industry
Biotechnology
IPO Date
2020-09-08
Stock Exchange
NASDAQ
Ticker
SLN
PE Ratio
[-4.13]
ROE
[-121.71%]
Current Ratio
[9.83]
Dividend Yield
[0%]
Enterprise Value
[310.47M]
Dividend History
The ROE as of June 2026 (TTM) for Silence Therapeutics plc (SLN) is -121.71%
According to Silence Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is -121.71%. This represents a change of 315.19% compared to the average of -29.31% of the last 4 quarters.
Silence Therapeutics plc (SLN) Historical ROE (quarterly & annually)
How has SLN ROE performed in the past?
The mean historical ROE of Silence Therapeutics plc over the last ten years is -155.35%. The current -121.71% ROE has changed -21.66% with respect to the historical average. Over the past ten years (40 quarters), SLN's ROE was at its highest in in the June 2022 quarter at 251.88%. The ROE was at its lowest in in the March 2022 quarter at -192.58%.
Average
-155.35%
Median
-117.94%
Minimum
-462.23%
Maximum
-3.09%
Silence Therapeutics plc (SLN) ROE by Quarter and Year
Discovering the peaks and valleys of Silence Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.60%
Maximum Annual ROE = -3.09%
Minimum Annual Increase = -80.16%
Minimum Annual ROE = -462.23%
| Year | ROE | Change |
|---|---|---|
| 2025 | -142.23% | 236.18% |
| 2024 | -42.31% | -78.50% |
| 2023 | -196.73% | 5.83% |
| 2022 | -185.90% | -59.78% |
| 2021 | -462.23% | 28.66% |
| 2020 | -359.28% | 283.63% |
| 2019 | -93.65% | 78.32% |
| 2018 | -52.52% | 1.60% |
| 2017 | -3.09% | -80.16% |
| 2016 | -15.58% | 41.65% |
Silence Therapeutics plc (SLN) Average ROE
How has SLN ROE performed in the past?
The current ROE of Silence Therapeutics plc (SLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-127.09%
5-year avg
-205.88%
10-year avg
-155.35%
Silence Therapeutics plc (SLN) ROE vs. Peers
How is SLN’s ROE compared to its peers?
Silence Therapeutics plc’s ROE is greater than Contineum Therapeutics, Inc. Class A Common Stock (-27.09%), greater than Amarin Corporation plc (-7.34%), greater than Kyverna Therapeutics, Inc. (-81.87%), greater than Aldeyra Therapeutics, Inc. (-57.34%), greater than Capricor Therapeutics, Inc. (-59.27%), greater than Lexeo Therapeutics, Inc. Common Stock (-47.48%), greater than Lyell Immunopharma, Inc. (-85.71%), greater than Mereo BioPharma Group plc (-81.25%), greater than Alto Neuroscience, Inc. (-47.22%), greater than AC Immune S.A. (-123.98%),
| Company | ROE | Market cap |
|---|---|---|
| -27.09% | $444.15M | |
| -7.34% | $315.21M | |
| -81.87% | $352.74M | |
| -57.34% | $106.17M | |
| -59.27% | $1.18B | |
| -47.48% | $343.14M | |
| -85.71% | $315.01M | |
| -81.25% | $48.68M | |
| -47.22% | $753.47M | |
| -123.98% | $235.10M |
Build a custom stock screener for Silence Therapeutics plc (SLN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Silence Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Silence Therapeutics plc (SLN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Silence Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Silence Therapeutics plc's ROE?
How is the ROE calculated for Silence Therapeutics plc (SLN)?
What is the highest ROE for Silence Therapeutics plc (SLN)?
What is the 3-year average ROE for Silence Therapeutics plc (SLN)?
What is the 5-year average ROE for Silence Therapeutics plc (SLN)?
How does the current ROE for Silence Therapeutics plc (SLN) compare to its historical average?